mercredi 11 septembre 2019

Onco Actu du 11 septembre 2019


1. BIOLOGIE



Breast Cancer Cells 'Stick Together' to Spread Through The Body During Metastasis [Johns Hopkins]











The structure of a T-cell mechanosensor [Nature]











1.5 PRIX LASKER



Celebrating the 2019 Lasker Awards: A Cell Collection [Cell]











Lasker Awards Honor Advances in Modern Immunology [NY Times]











The Team that Just Wouldn’t Quit and a New Paradigm in Cancer Drug Discovery [Cell]










Immune-cell pioneers win prestigious Lasker medical award [Nature]











Discovery of 2 Distinctive Lineages of Lymphocytes, T Cells and B Cells, as the Basis of the Adaptive Immune System and Immunologic Function [JAMA]










Biomarker-Driven Drug Discovery in Cancer—Trastuzumab Development [JAMA]











Moving from Cancer Genetics to Therapy [Cell]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Is Juul the new big tobacco? Wave of lawsuits signal familiar problems [The Guardian]











Bloomberg Takes on Vaping After Giving $1 Billion to Fight Tobacco [NY Times]











Factbox: What we know about U.S. vaping illnesses [Reuters]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



European Labs Continue to Validate and Implement TMB, Facing Down Cutoff Discordance Concerns [Genome Web]











4.12 BIOPSIES LIQUIDES



New blood test for prostate cancer is highly-accurate and avoids invasive biopsies [Queen Mary University of London]











Simple blood test for prostate cancer could save men from needless biopsies and 'over-treatment' [The Telegraph]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



When should NHS contact patients over faulty genes? [University of Exeter]










Scientists call for population wide BRCA testing for higher risk group [Queen Mary University of London]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



A Liquid Biopsy Test Can Identify Patients Who May Respond to Immune Checkpoint Blockade [AACR]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Italian gene therapy player draws new investor from China for its answer to CAR-T relapses [EndPoints]











5.13 WCLC



At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More [Xconomy]











5.13.1 WCLC - IMMUNOTHÉRAPIES



WCLC: Roche's Tecentriq comes up short in squamous lung cancer, leaving Merck's Keytruda 'unchallenged' [Fierce Pharma]











WCLC: Bristol-Myers' Opdivo spurs fivefold increase in long-term lung cancer survival [Fierce Pharma]











IMpower131: Final Overall Survival Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC [IASLC]











KEYNOTE-024 Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer [IASLC]











Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1 [Merck]











Patients Taking Nivolumab Experience Five-Fold Increase in Overall Survival Compared to Chemotherapy [IASLC]











Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients [BMS]











5.13.1.1 WCLC - BIOMARQUEURS



WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win [Fierce Pharma]










Biomarker data help Merck case for wide use of Keytruda combo [Biopharma Dive]











5.13.4 WCLC - DIVERS



Europeans Face Significant Challenges to Participate in Lung Cancer Clinical Trials [IASLC]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them [STAT]











5.6 ESMO



GSK to present data from its innovative oncology portfolio at ESMO Congress 2019 [GSK]











6.6 PUBLICATIONS



Open-access megajournals lose momentum as the publishing model matures [Science]











What’s next for Registered Reports? [Nature]











Rise of the platforms [Nature Physics]











6.7 DMP, BIG DATA & APPLIS



Google, Mayo Clinic strike sweeping partnership on patient data [STAT]